Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

| More on:
Contented looking man leans back in his chair at his desk and smiles.

Image Source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With so many shares to choose from on the Australian share market, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you.

Three top ASX shares that leading brokers have named as buys this week are listed below. Here's why they are bullish on them:

ResMed Inc. (ASX: RMD)

According to a note out of Citi, its analysts have retained their buy rating and $36.00 price target on this sleep disorder treatment company's shares. This follows the release of trial results from Eli Lilly And Co (NYSE: LLY) in relation to tirzepatide (Mounjaro) as a treatment of moderate-to-severe obstructive sleep apnoea (OSA) in adults with obesity. While Citi acknowledges that there is a risk that a portion of patients with mild OSA symptoms might drop CPAP devices over time because of the weight loss drug, it doesn't appear overly concerned. Particularly given that stronger results were achieved from a combination of Mounjaro and CPAP devices. The ResMed share price is trading at $27.83 today.

South32 Ltd (ASX: S32)

A note out of Macquarie reveals that its analysts have retained their outperform rating on this mining giant's shares with an improved price target of $4.50. This follows the broker's review of commodity prices. Macquarie remains very positive on a number of commodities that South32 produces such as aluminium, met coal, and nickel. In light of this, it has boosted its earnings estimates for the coming years and has named South32 as its top pick among the large cap miners right now. The South32 share price is fetching $3.63 on Monday afternoon.

Treasury Wine Estates Ltd (ASX: TWE)

Analysts at Morgans have retained their add rating on this wine giant's shares with an improved price target of $15.03. The broker was pleased with a recent update on its Penfolds business and notes that management has reaffirmed its earnings guidance for FY 2024. It was even more pleased to see that its earnings growth is likely to accelerate next year thanks to US luxury availability, the acquisition of DAOU Vineyards, and the recent removal of Chinese wine tariffs. Overall, the broker sees potential for Treasury Wines to deliver double-digit earnings growth over the medium term if management can execute on its plans. The Treasury Wine share price is trading at $12.27 at the time of writing.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor James Mickleboro has positions in ResMed and Treasury Wine Estates. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group and ResMed. The Motley Fool Australia has positions in and has recommended Macquarie Group and ResMed. The Motley Fool Australia has recommended Treasury Wine Estates. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Broker Notes

Should you pounce on ResMed shares at around $28?

Here's what top broker Citi says.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

ANZ ASX 200 banks capital return Group of investors madly grabbing for cash on city street.
Healthcare Shares

ResMed shares rebounding as investors rush to buy the dip

ResMed is rising as ASX investors buy the dip following yesterday's 13% share price dive.

Read more »

A group of stockbrokers sit in a room with several computer screens in front of them as they discuss the Zip share price and Zip's merger with Sezzle
Broker Notes

Why these 3 ASX 200 shares just gained significant broker upgrades

The brokers just boosted their outlooks for these ASX 200 shares. But why?

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Broker Notes

Buy this ASX 200 stock for 'stability and growth potential'

One analyst has good things to say about this stock.

Read more »

A female executive smiles as she carries out business on her mobile phone.
Broker Notes

Buy Telstra shares due to its 'excessive' discount

This telco giant's shares could be unnecessarily cheap according to Bell Potter.

Read more »

Two businesspeople walk together in an office, smiling as they enjoy a good business relationship.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A man sees some good news on his phone and gives a little cheer.
Broker Notes

These ASX shares could rise 20% and ~40%

Analysts think buyers of these shares could generate big returns over the next 12 months.

Read more »